United Therapeutics (UTHR) director sells 2,000 shares after stock option exercise
Rhea-AI Filing Summary
United Therapeutics director Tommy G. Thompson reported an option exercise and related share sales. He exercised stock options for 2,000 shares of common stock at $101.80 per share and received 2,000 shares on March 26, 2026. He then sold a total of 2,000 common shares in three open-market transactions at weighted average prices of $537.6192, $539.2451, and $540.1750 per share. After these transactions, he holds 8,480 common shares directly, plus indirect holdings of 8,200 shares held by a trust and 5,800 shares held by a family LLC. A footnote also notes 880 additional shares are scheduled to be issued on or about July 8, 2026 from previously vested deferred RSUs.
Positive
- None.
Negative
- None.
Insights
Director exercised options for 2,000 shares and sold all of them while retaining a meaningful equity stake.
The filing shows director Tommy G. Thompson exercised stock options covering 2,000 United Therapeutics shares at an exercise price of $101.80 and received 2,000 common shares. On the same date, he sold 2,000 shares in three open-market transactions around $538–$540 per share.
These moves represent a classic exercise-and-sell pattern, converting an option position into cash and eliminating the related derivative exposure. Following the transactions, Thompson still owns 8,480 shares directly, with additional indirect stakes of 8,200 shares via a trust and 5,800 via a family LLC.
A footnote also indicates 880 deferred RSU shares expected to be issued on or about July 8, 2026. Overall, this looks like routine equity compensation management rather than a transformational change in insider ownership, as he maintains sizable direct and indirect holdings after the sales.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 2,000 | $0.00 | -- |
| Exercise | Common Stock | 2,000 | $101.80 | $204K |
| Sale | Common Stock | 275 | $537.6192 | $148K |
| Sale | Common Stock | 1,414 | $539.2451 | $762K |
| Sale | Common Stock | 311 | $540.175 | $168K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Includes 880 shares of common stock to be issued on or about July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares. This transaction was executed in multiple trades at prices ranging from $537.43 to $538.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $538.63 to $539.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $539.64 to $540.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
